Cite
HARVARD Citation
Fellström, B. et al. (2017). Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 389 (10084), pp. 2117-2127. [Online].